
Opinion|Videos|January 10, 2025
Assessing New Therapies for Retinal Diseases
Panelists discuss how aflibercept 8 mg demonstrates improved durability and maintenance of visual gains compared with 2-mg dosing, potentially reducing treatment burden while maintaining a similar safety profile.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- New Therapies:
- Aflibercept 8 mg
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
IGS 2026: Clinical pearls for detecting pre-perimetric glaucoma
2
IGS 2026: The expanding role of artificial intelligence in ophthalmology
3
Broadening horizons: Expanding your surgical portfolio with SMILE pro for Hyperopia
4
IGS 2026: Population-based normative data could transform AI in glaucoma
5





























